Haleon HLN
NYSE HLN
$9.87 +0.00 (+0.00%)
As of: Aug 20, 2026 · 3:59 PM EDT

Haleon (HLN) Total Non-Current Liabilities (2021 - 2026)

Haleon's (HLN) quarterly Total Non-Current Liabilities came in at -$13.3 billion in Q2 2026, up 11.61% on a QoQ basis from -$15.0 billion in Q4 2025.

Haleon (HLN) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Haleon (HLN) has 6 years of Total Non-Current Liabilities data on file, last reported at -$13.3 billion in Q2 2026.

  • Quarterly Total Non-Current Liabilities changed N/A year-over-year to -$13.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$13.3 billion (changed N/A YoY) and the FY2025 annual result came in at -$14.9 billion, down 195.03% from the prior year.
  • Total Non-Current Liabilities rose to -$13.3 billion in Q2 2026, from -$15.0 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $16.4 billion in Q4 2022 to a low of -$17.4 billion in Q2 2022.
  • A 5-year average of -$3.4 billion and a median of -$13.6 billion in 2024 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 226.04% — and 2025, when it plunged 195.32%.
  • Tracing HLN's Total Non-Current Liabilities over 5 years: stood at $16.4 billion in 2022, then declined by 4.03% to $15.7 billion in 2023, then climbed by 0.09% to $15.8 billion in 2024, then slumped by 195.32% to -$15.0 billion in 2025, then gained by 11.61% to -$13.3 billion in 2026.
  • The last three Total Non-Current Liabilities figures came in at -$13.3 billion (Q2 2026), -$15.0 billion (Q4 2025), and $15.8 billion (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 43.83 Bn 42.86 Bn - -13.28 Bn
2 Teva Pharmaceutical Industries 42.87 Bn 39.22 Bn 2.15 Bn 16.45 Bn
3 Zoetis 31.41 Bn 29.73 Bn 1.05 Bn 11.64 Bn
4 Takeda Pharmaceutical 28.55 Bn 22.75 Bn 5.10 Bn 33.50 Bn
5 United Therapeutics 22.08 Bn 19.42 Bn 683.80 Mn 607.80 Mn
6 Viatris 18.73 Bn 17.84 Bn 1.46 Bn 18.76 Bn
7 Neurocrine Biosciences 15.44 Bn 15.05 Bn 935.80 Mn 1.37 Bn
8 Elanco Animal Health 11.75 Bn 11.22 Bn 798.00 Mn 6.42 Bn
9 Dr Reddys Laboratories 10.11 Bn 9.94 Bn - 334.00 Mn
10 Alkermes 8.02 Bn 7.37 Bn 397.90 Mn 2.45 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 -13.28 Bn
Dec 31, 2025 -15.02 Bn
Dec 31, 2024 15.76 Bn
Jun 30, 2024 -13.97 Bn
Dec 31, 2023 15.75 Bn
Jun 30, 2023 -15.78 Bn
Dec 31, 2022 16.41 Bn
Jun 30, 2022 -17.39 Bn
Dec 31, 2021 5.03 Bn